AVTX - CIK 0001534120
The table below shows Avalo Therapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$51.46M | -$49.06M | -$30.68M | -$26.75M | -$70.89M | -$40.54M |
| Capital expenditure | - | - | - | $95.00K | $113.00K | $63.00K |
| Investing cash flow | -$81.72M | $356.00K | -$133.00K | -$95.00K | -$113.00K | $11.13M |
| Dividends paid | - | - | - | - | - |
Avalo Therapeutics, Inc. reported operating cash flow of -$51.46M for fiscal year 2025. That is down 4.9% from -$49.06M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$14.57M (FY 2016) to -$51.46M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $14.59M | $175.85M | $25.04M | -$14.70M | $106.76M | $44.78M |